Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer

Abstract

Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands in tumors that have acquired resistance. Importantly, sensitivity to taxanes is recovered after long-term drug interruption. The characterization of this chemoresistant CD49f+ cells provides a unique opportunity to identify novel targets for the treatment of chemoresistant TNBC.

Keywords

• cd49f tumor-initiating cells
• chemoresistance
• docetaxel
• pdx (patient-derived orthoxenografts)
• triple negative breast cancer (tnbc)